Prana Biotechnology secures orphan designation for PBT434 in MSA

Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple System Atrophy (MSA). Prana Biotechnology claims that its application was based on the proposed use of the molecule as a treatment for MSA, including the medical and scientific rationale. The Australian biotech More...

by pharmanewsdaily | Published 2 weeks ago
By pharmanewsdaily On Wednesday, January 30th, 2019
0 Comments

AgeneBio enrolls first patient in AGB101 phase 3 trial in MCI due to AD

AgeneBio, a US-based CNS biopharma company, enrolled the first patient in a phase 3 clinical trial to study the efficacy of AGB101 for the treatment of amnestic Mild Cognitive Impairment caused by Alzheimer’s More...

By pharmanewsdaily On Sunday, January 27th, 2019
0 Comments

Spectrum offloads seven hematology/oncology drugs to Acrotech in $300m deal

US biopharma company Spectrum Pharmaceuticals has agreed to offload seven of its FDA-approved hematology/oncology drugs to Acrotech Biopharma, a subsidiary of Aurobindo Pharma USA, in a deal worth around $300 million. The More...

By pharmanewsdaily On Saturday, January 26th, 2019
0 Comments

FDA accepts X-Rx new drug application for IPD drug X-165

US biotech company X-Rx said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for X-165, a small molecule inhibitor of Autotaxin X-165, which is being developed More...

By pharmanewsdaily On Saturday, January 26th, 2019
0 Comments

Tamr joins Accenture’s life sciences ecosystem to help drive innovation in drug discovery and scientific research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more More...

By pharmanewsdaily On Saturday, January 26th, 2019
0 Comments

Clovis PARP inhibitor Rubraca gets EC approval for relapsed ovarian cancer

Rubraca EC approval : US biotech company Clovis Oncology has secured approval for an additional indication for its cancer drug Rubraca (rucaparib) in Europe – as maintenance treatment for adult women whose More...

By pharmanewsdaily On Sunday, January 20th, 2019
0 Comments

Eusa Pharma acquires iMCD drug Sylvant global rights from Janssen

Eusa Pharma has completed acquisition of the global rights of idiopathic multicentric Castleman’s disease drug (iMCD drug) Sylvant (siltuximab) from Janssen Sciences Ireland in an all-cash deal worth $115 million. The More...

By pharmanewsdaily On Sunday, January 20th, 2019
0 Comments

Takeda acquisition of Shire : Japanese pharma company completes $62bn acquisition

Takeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish biotech company with a focus on rare diseases, for $62 billion, as per More...

By pharmanewsdaily On Sunday, January 13th, 2019
0 Comments

Lilly to acquire Stamford biopharma company Loxo Oncology in $8bn deal

Lilly acquisition of Loxo Oncology : US pharma giant Eli Lilly and Company (Lilly) has signed an all-cash deal worth $8 billion to acquire Loxo Oncology, a Connecticut-based biopharma company, as per the latest More...

By pharmanewsdaily On Sunday, January 6th, 2019
0 Comments

US biotech company Celgene to be acquired by Bristol-Myers Squibb for $74bn

Bristol-Myers Squibb acquisition of Celgene : US biotech company Celgene has agreed to be acquired by Bristol-Myers Squibb in a stock and cash deal worth about $74 billion, as per the latest pharma acquisition news. The More...